Davis's Drug Guide
glofitamab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
gloe-fit-ah-mab
Trade Name(s)
- Columvi
Ther. Class.
Pharm. Class.
T-cell engagers
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Glofitamab." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580021/9/glofitamab.
Vallerand AHA, Sanoski CAC, . Glofitamab. Davis's Drug Guide. F.A. Davis Company; 2025. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580021/9/glofitamab. Accessed January 15, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Glofitamab. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580021/9/glofitamab
Vallerand AHA, Sanoski CAC, . Glofitamab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 January 15]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580021/9/glofitamab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - glofitamab
ID - 3580021
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/3580021/9/glofitamab
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
